Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

Aardvark's lead drug ARD-101 targets PWS and HO with trials underway and funding secured through 2027 after a $94.2 million ...

FDA approval of VYKAT XR for hyperphagia in Prader-Willi Syndrome marks a major milestone for Soleno Therapeutics.

Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the 10 Unstoppable Stocks to Buy According to Hedge Funds. On June 23, TD ...

Soleno Therapeutics, Inc. has announced positive results from its clinical program for VYKAT™ XR (diazoxide choline) extended-release tablets, aimed at treating hyperphagia in individuals with ...

First prescriptions delivered to individuals with PWSREDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company ...

Soleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference Provided by GlobeNewswire Jun 25, 2025, 12:00:00 PM ...

Soleno Therapeutics Announces VYKAT(TM) XR Launch Provided by GlobeNewswire Apr 14, 2025 11:00am. REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ...

REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare ...

Soleno Therapeutics Announces VYKAT(TM) XR Launch. Press Release Date 04-14-2025. First prescriptions delivered to individuals with PWS. REDWOOD CITY, Calif., April 14, 2025 ...

Soleno Therapeutics announced the U.S. commercial availability of VYKAT XR extended-release tablets, the company’s treatment for hyperphagia in patients four years of age and older with Prader ...